ReviewFrontiers in medicine2025
Beyond the hype: re-evaluating efficacy metrics and modeling rigor for MSC-EVs-based therapy in acute brain injury.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute brain injuries (ABI), such as traumatic brain injury, stroke, hypoxia-induced brain injury, and cardiac arrest, are critical and life-threatening conditions that contribute to substantial mortality and long-term disability. Despite extensive translational efforts, no effective therapy has improved long-term functional outcomes, highlighting a critical unmet need. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutic platform, offering multifaceted repair capabilities. This review synthesizes current evidence supporting the neuroprotective effects of MSC-EVs, which operate through synchronized immunomodulation, anti-apoptotic signaling, enhancement of neurogenesis, and stimulation of angiogenesis. We further delineated the fundamental EVs biology, including biogenesis pathways, spatiotemporal biodistribution, and blood-brain barrier (BBB) trafficking mechanisms that underpin therapeutic efficacy. Collectively, we established MSC-EV cargo as a strategic solution to unmet neuroprotective needs while mapping clinical translation roadmaps to accelerate the rational development of regenerative neurotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.